|Assessment Status||Rapid Review complete|
|Indication||For paediatric patients aged three months and older for the treatment of: Complicated intra-abdominal infection (cIAI); Complicated urinary tract infection (cUTI), including pyelonephritis; Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP); Infections due to aerobic Gram-negative organisms in patients with limited treatment options|
|Rapid review commissioned||09/02/2021|
|Rapid review completed||04/03/2021|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that of ceftazidime-Avibactam (Zavicefta®) not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.